Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Free Speech--0710

This article was originally published in RPM Report

Executive Summary

Government and industry officials discuss the new drug safety law and the fortunes of the pharmaceutical industry on the campaign trail.

You may also be interested in...



Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

Running Away from Part D: No Love for New Rx Benefit on Campaign Trail

It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.

The IRA And US FDA: How Will Agency View Any Drug Development Changes?

US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel